Table I.
Patient demographics and clinical features
| Patient no. | Sex | Age (y) | Guttate psoriasis duration before ustekinumab (mo) | Distribution of lesions | Prior treatments | Ustekinumab dosage (schedule) | Serious adverse effects | No. of injections until clear | Total no. of injections | Length of remission (mo) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 38 | 12 | Scalp, upper/lower extremities, and trunk | Clobetasol, oral prednisone, cyclosporine | 90 mg once | None | 1 | 1 | 16 |
| 2 | Female | 25 | 36 | Trunk, upper/lower extremities, face, and scalp | Clobetasol, phototherapy | 90 mg (weeks 0 and 8), then 45 mg (weeks 23, 35, and 58) | None | 2 | 5 | 9 |
| 3 | Male | 29 | 3 | Trunk, upper/lower extremities, face, and buttocks | Clobetasol, oral prednisone, cyclosporine | 45 mg (weeks 0, 8, 18, and 30) | None | 3 | 4 | 20 |
| 4 | Male | 26 | 4 | Scalp, axillae, neck, chest, extremities, abdomen, and buttocks | Clobetasol, pimecrolimus cyclosporine | 90 mg (weeks 0, 4, then every 8 weeks) | None | 2 | 18 | 24 |
| 5 | Female | 42 | 36 | Trunk, extremities, and scalp | Phototherapy, cyclosporine | 45 mg (weeks 0 and 4) | None | 2 | 2 | 3 |
| 6 | Female | 35 | 3 | Trunk and extremities | Clobetasol, cyclosporine, apremilast | 90 mg (weeks 0 and 4) | None | 2 | 2 | 7 |